UHPLC-MS/MS method for the quantification of ultra-traces of irinotecan and its metabolites in red blood cells and plasma to detect caregivers' contamination.
LC-MS/MS
antineoplastic drug
biomonitoring
irinotecan
occupational exposure
Journal
Drug testing and analysis
ISSN: 1942-7611
Titre abrégé: Drug Test Anal
Pays: England
ID NLM: 101483449
Informations de publication
Date de publication:
28 Jun 2023
28 Jun 2023
Historique:
revised:
12
06
2023
received:
14
02
2023
accepted:
14
06
2023
medline:
29
6
2023
pubmed:
29
6
2023
entrez:
29
6
2023
Statut:
aheadofprint
Résumé
The occupational exposure of caregivers to antineoplastic agents has been demonstrated since 1979. Since the early 1990s, numerous studies from several countries have demonstrated the contamination of care facilities by antineoplastic drugs. As it is easier to sample, most contamination measurements in workers are carried out in urine sample. The distribution and elimination half-lives of irinotecan suggest that blood can be considered as better than urine for the biomonitoring of a potential contamination of healthcare workers. We describe here the development and the validation of a UHPLC-MS/MS method to simultaneously quantify irinotecan, and two of its main metabolites, APC and SN-38, at ultra-trace levels in plasma and red blood cells (RBC). This method has been applied to blood samples collected from several healthcare services in a French comprehensive cancer center. The results demonstrate that the method is sensitive enough to identify a contamination of healthcare workers by irinotecan and SN-38 at very low concentrations. Moreover, the results show that analysis of RBC is of great interest and complementary to that of serum.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : European Regional Development Fund
Organisme : Région Normandie
Organisme : Regional Health Agency of Normandy
Informations de copyright
© 2023 John Wiley & Sons Ltd.
Références
Falck K, Gröhn P, Sorsa M, Vainio H, Heinonen E, LarsR H. MUTAGENICITY IN URINE OF NURSES HANDLING CYTOSTATIC DRUGS. Lancet. 1979;313(8128):1250-1251. doi:10.1016/S0140-6736(79)91939-1
Cunha KS. Comparison of camptothecin derivatives presently in clinical trials: genotoxic potency and mitotic recombination. Mutagenesis. 2002;17(2):141-147. doi:10.1093/mutage/17.2.141
Rothenberg ML, Kuhn JG, Schaaf LJ, et al. Alternative dosing schedules for irinotecan. Oncology (Williston Park). 1998;12:68-71.
National Institute for Occupational Safety and Health (NIOSH). (2004) Preventing occupational exposure to antineoplastic and other hazardous drugs in health care settings. Accessed October 1, 2020. https://www.cdc.gov/niosh/docs/2004-165/pdfs/2004-165.pdf?id=10.26616/NIOSHPUB2004165
Connor TH, McDiarmid MA. Preventing occupational exposures to antineoplastic drugs in health care settings. CA Cancer J Clin. 2006;56(6):354-365. doi:10.3322/canjclin.56.6.354
Bhatt A, Mittal S, Gopinath KS. Safety considerations for health care workers involved in Cytoreductive surgery and perioperative chemotherapy. Indian J Surg Oncol. 2016;7(2):249-257. doi:10.1007/s13193-016-0503-7
Sugarbaker PH. Peritonectomy Procedures. In: Ceelen WP, ed. Peritoneal Carcinomatosis. Springer; 2007:247-264. doi:10.1007/978-0-387-48993-3_15
de Bree E. Optimal drugs for HIPEC in different tumors. J BUON off J Balk Union Oncol. 2015;20(Suppl 1):S40-S46.
Elias D, Goere D, Blot F, et al. Optimization of Hyperthermic intraperitoneal chemotherapy with Oxaliplatin plus irinotecan at 43°C after compete Cytoreductive surgery: mortality and morbidity in 106 consecutive patients. Ann Surg Oncol. 2007;14(6):1818-1824. doi:10.1245/s10434-007-9348-1
Barale R, Sozzi G, Toniolo P, et al. Sister-chromatid exchanges in lymphocytes and mutagenicity in urine of nurses handling cytostatic drugs. Mutat Res Toxicol. 1985;157(2-3):235-240. doi:10.1016/0165-1218(85)90121-1
Benhamou S, Callais F, Sancho-Garnier H, Min S, Courtois YA, Festy B. Mutagenicity in urine from nurses handling cytostatic agents. Eur J Cancer Clin Oncol. 1986;22(12):1489-1493. doi:10.1016/0277-5379(86)90085-4
Tanimura M, Yamada K, Sugiura S, et al. An environmental and biological study of occupational exposure to cyclophosphamide in the pharmacy of a Japanese community hospital designated for the treatment of cancer. J Health Sci. 2009;55(5):750-756. doi:10.1248/jhs.55.750
Chabot GG. Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet. 1997;33:245-259. doi:10.2165/00003088-199733040-00001
de Jong FA, Mathijssen RHJ, de Bruijn P, Loos WJ, Verweij J, Sparreboom A. Determination of irinotecan (CPT-11) and SN-38 in human whole blood and red blood cells by liquid chromatography with fluorescence detection. J Chromatogr B. 2003;795(2):383-388. doi:10.1016/S1570-0232(03)00574-9
Rivory LP, Haaz MC, Canal P, Lokiec F, Armand JP, Robert J. Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials. Clin Cancer Res off J am Assoc Cancer Res. 1997;3:1261-1266.
Izzo V, Charlier B, Bloise E, et al. A UHPLC-MS/MS-based method for the simultaneous monitoring of eight antiblastic drugs in plasma and urine of exposed healthcare workers. J Pharm Biomed Anal. 2018;154:245-251. doi:10.1016/j.jpba.2018.03.024
European Medicines Agency (EMA). (2012) Committee for Medicinal Products for human use (CHMP), guideline on bioanalytical method validation. https://www.ema.europa.eu/documents/scientific-guideline/guideline-bioanalytical-method-validation_en.pdf
Food and Drug Administration. FDA guidance for industry: bioanalytical method validation. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research; 2018. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioanalytical-method-validation-guidance-industry
Basu S, Zeng M, Yin T, Gao S, Hu M. Development and validation of an UPLC-MS/MS method for the quantification of irinotecan, SN-38 and SN-38 glucuronide in plasma, urine, feces, liver and kidney: application to a pharmacokinetic study of irinotecan in rats. J Chromatogr B. 2016;1015-1016:34-41. doi:10.1016/j.jchromb.2016.02.012
Gao S, Tao Z, Zhou J, et al. One-step solid extraction for simultaneous determination of eleven commonly used anticancer drugs and one active metabolite in human plasma by HPLC-MS/MS. J Anal Methods Chem. 2018;2018:7967694. doi:10.1155/2018/7967694
Nussbaumer S, Fleury-Souverain S, Antinori P, et al. Simultaneous quantification of ten cytotoxic drugs by a validated LC-ESI-MS/MS method. Anal Bioanal Chem. 2010;398(7-8):3033-3042. doi:10.1007/s00216-010-4243-1
Ahn G, Park DM, Park JW, et al. A rapid, simple and reliable HPLC-triple quadrupole tandem mass spectrometer method for a simultaneous quantification of irinotecan and its active metabolite 7-ethyl-10-hydroxycamptothecin (SN38) in mouse plasma: a new method for the quantification of irinotecan and SN38. Biomed Chromatogr. 2014;28(7):919-922. doi:10.1002/bmc.3134
Edwards JL, Edwards RL, Reid KR, Kennedy RT. Effect of decreasing column inner diameter and use of off-line two-dimensional chromatography on metabolite detection in complex mixtures. J Chromatogr A. 2007;1172(2):127-134. doi:10.1016/j.chroma.2007.09.075
Lesellier E. Extension of the carotenoid test to superficially porous C18 bonded phases, aromatic ligand types and new classical C18 bonded phases. J Chromatogr A. 2012;1266:34-42. doi:10.1016/j.chroma.2012.09.068
Herviou P, Richard D, Roche L, et al. Determination of irinotecan and SN38 in human plasma by TurboFlow™ liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2016;118:284-291. doi:10.1016/j.jpba.2015.10.044
Chen X, Peer CJ, Alfaro R, Tian T, Spencer SD, Figg WD. Quantification of irinotecan, SN38, and SN38G in human and porcine plasma by ultra high-performance liquid chromatography-tandem mass spectrometry and its application to hepatic chemoembolization. J Pharm Biomed Anal. 2012;62:140-148. doi:10.1016/j.jpba.2012.01.008
Dumez H, Guetens G, De Boeck G, et al. In vitro partition of irinotecan (CPT-11) in human volunteer blood: the influence of concentration, gender and smoking. Anticancer Drugs. 2005;16(8):893-895. doi:10.1097/01.cad.0000175584.86198.ac
Combes O, Barré J, Duché J-C, et al. In vitro binding and partitioning of irinotecan (CPT-11) and its metabolite, SN-38, in human blood. Invest New Drugs. 2000;18(1):1-5. doi:10.1023/A:1006379730137
Benoist H, Breuil C, Le Neindre B, Lagadu S, Delépée R, Saint-Lorant G. Does equipment change impact blood contamination with irinotecan and its two major metabolites in a centralized cytotoxic pharmacy unit? J Oncol Pharm Pract. 2020;26(8):1823-1828. doi:10.1177/1078155220905013
Saint-Lorant G, Rodier S, Guilloit J-M, et al. Are surgeons' blood contaminated by irinotecan, its major metabolites and platinum compounds during HIPEC? Pleura Peritoneum. 2021;6(2):49-55. doi:10.1515/pp-2020-0141
Béchet V, Benoist H, Beau F, et al. Blood contamination of the pharmaceutical staff by irinotecan and its two major metabolites inside and outside a compounding unit. J Oncol Pharm Pract. 2022;28(4):777-784. doi:10.1177/10781552211012059
Pirot C, Benoist H, Lagadu S, Delépée R, Saint-Lorant G. Impact of low- and high-risk caregivers and non-caregivers handling irinotecan on blood contamination in oncology day hospital units. J Oncol Pharm Pract. 2022;29(4):905-911. doi:10.1177/10781552221090965